Personalis (PSNL) to Release Earnings on Thursday

Personalis (NASDAQ:PSNL) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Personalis to post earnings of ($0.31) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Personalis Price Performance

Shares of PSNL opened at $9.00 on Thursday. The firm has a 50-day simple moving average of $8.80 and a two-hundred day simple moving average of $7.80. The stock has a market cap of $799.20 million, a PE ratio of -10.23 and a beta of 1.98. Personalis has a 1-year low of $2.83 and a 1-year high of $11.50.

Insider Transactions at Personalis

In related news, CFO Aaron Tachibana sold 103,668 shares of Personalis stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the transaction, the chief financial officer directly owned 164,458 shares in the company, valued at approximately $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

Hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC lifted its stake in Personalis by 23.4% in the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares during the last quarter. Brevan Howard Capital Management LP acquired a new stake in shares of Personalis in the 3rd quarter valued at $97,000. Squarepoint Ops LLC purchased a new stake in shares of Personalis during the 3rd quarter worth $123,000. BNP Paribas Financial Markets grew its stake in shares of Personalis by 129.4% during the third quarter. BNP Paribas Financial Markets now owns 14,796 shares of the company’s stock worth $96,000 after purchasing an additional 8,345 shares in the last quarter. Finally, FourThought Financial Partners LLC purchased a new position in Personalis in the third quarter valued at $86,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PSNL shares. Needham & Company LLC lifted their target price on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. HC Wainwright boosted their price objective on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Lake Street Capital reissued a “buy” rating and set a $11.00 target price on shares of Personalis in a research note on Wednesday, November 5th. Finally, Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.86.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.